Global HIV Diagnosis

HIV Diagnosis Comprehensive Study by Type (Consumables (Assays and Kits & Reagents, and other Consumables), Instruments, Software & Services), Test Type (Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Tests, Tests for Early Infant Diagnosis, Tests for Viral Identification), End User (Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings, Others) Players and Region - Global Market Outlook to 2030

HIV Diagnosis Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About HIV Diagnosis
Blood tests are the most common way to diagnose HIV, which checks the presence of the Human Immunodeficiency Virus (HIV) in a human body. Diagnosis of HIV includes several tests such as ELISA Test, Saliva Test, Home Test, Viral Test, and Western Test. Rising awareness about HIV and growth in the number of affected persons has increased the demand for the latest technology to serve the diagnosis purpose properly. The increasing prevalence of HIV infection worldwide will majorly boost HIV diagnostics market growth over the forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global HIV Diagnosis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (United States), Danaher Corporation (United States), Thermo-Fisher Scientific Inc. (United States), Merck KGaA (Germany), Becton, Dickinson, and Company (United States), Hologic, Inc. (United States), Alere Inc. (United States) and Bio-Rad Laboratories (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global HIV Diagnosis market by Type (Consumables (Assays and Kits & Reagents, and other Consumables), Instruments and Software & Services) and Region.



On the basis of geography, the market of HIV Diagnosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Test Type, the sub-segment i.e. Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests) will boost the HIV Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Diagnostic Laboratories will boost the HIV Diagnosis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Use of Home Access Kits and Instruments

Market Growth Drivers:
Increasing Prevalence of HIV/Aids across the Globe, Rising Number of Blood Transfusions and Blood Donations and Increasing Government Initiatives

Challenges:
Lack of Mandates for Nat in Developing Countries

Restraints:
High Cost of Nat

Opportunities:
Emerging Economies offer Lucrative Growth Opportunities for HIV Diagnosis

Market Leaders and their expansionary development strategies
In September 2020 - Roche announced U.S. Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.
In December 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug.


Key Target Audience
HIV Diagnosis Treatment Providers, Manufacturers of HIV Diagnosis Products, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Consumables (Assays and Kits & Reagents, and other Consumables)
  • Instruments
  • Software & Services
By Test Type
  • Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests)
  • Viral Load Tests
  • CD4 Tests
  • Tests for Early Infant Diagnosis
  • Tests for Viral Identification

By End User
  • Diagnostic Laboratories
  • Hospitals
  • Blood Banks
  • Home Care Settings
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of HIV/Aids across the Globe
      • 3.2.2. Rising Number of Blood Transfusions and Blood Donations
      • 3.2.3. Increasing Government Initiatives
    • 3.3. Market Challenges
      • 3.3.1. Lack of Mandates for Nat in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Increase in Use of Home Access Kits and Instruments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global HIV Diagnosis, by Type, Test Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global HIV Diagnosis (Value)
      • 5.2.1. Global HIV Diagnosis by: Type (Value)
        • 5.2.1.1. Consumables (Assays and Kits & Reagents, and other Consumables)
        • 5.2.1.2. Instruments
        • 5.2.1.3. Software & Services
      • 5.2.2. Global HIV Diagnosis by: Test Type (Value)
        • 5.2.2.1. Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests)
        • 5.2.2.2. Viral Load Tests
        • 5.2.2.3. CD4 Tests
        • 5.2.2.4. Tests for Early Infant Diagnosis
        • 5.2.2.5. Tests for Viral Identification
      • 5.2.3. Global HIV Diagnosis by: End User (Value)
        • 5.2.3.1. Diagnostic Laboratories
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Blood Banks
        • 5.2.3.4. Home Care Settings
        • 5.2.3.5. Others
      • 5.2.4. Global HIV Diagnosis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. HIV Diagnosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Siemens AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Diagnostics (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo-Fisher Scientific Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson, and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hologic, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alere Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bio-Rad Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global HIV Diagnosis Sale, by Type, Test Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global HIV Diagnosis (Value)
      • 7.2.1. Global HIV Diagnosis by: Type (Value)
        • 7.2.1.1. Consumables (Assays and Kits & Reagents, and other Consumables)
        • 7.2.1.2. Instruments
        • 7.2.1.3. Software & Services
      • 7.2.2. Global HIV Diagnosis by: Test Type (Value)
        • 7.2.2.1. Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests)
        • 7.2.2.2. Viral Load Tests
        • 7.2.2.3. CD4 Tests
        • 7.2.2.4. Tests for Early Infant Diagnosis
        • 7.2.2.5. Tests for Viral Identification
      • 7.2.3. Global HIV Diagnosis by: End User (Value)
        • 7.2.3.1. Diagnostic Laboratories
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Blood Banks
        • 7.2.3.4. Home Care Settings
        • 7.2.3.5. Others
      • 7.2.4. Global HIV Diagnosis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HIV Diagnosis: by Type(USD Million)
  • Table 2. HIV Diagnosis Consumables (Assays and Kits & Reagents, and other Consumables) , by Region USD Million (2018-2023)
  • Table 3. HIV Diagnosis Instruments , by Region USD Million (2018-2023)
  • Table 4. HIV Diagnosis Software & Services , by Region USD Million (2018-2023)
  • Table 5. HIV Diagnosis: by Test Type(USD Million)
  • Table 6. HIV Diagnosis Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests) , by Region USD Million (2018-2023)
  • Table 7. HIV Diagnosis Viral Load Tests , by Region USD Million (2018-2023)
  • Table 8. HIV Diagnosis CD4 Tests , by Region USD Million (2018-2023)
  • Table 9. HIV Diagnosis Tests for Early Infant Diagnosis , by Region USD Million (2018-2023)
  • Table 10. HIV Diagnosis Tests for Viral Identification , by Region USD Million (2018-2023)
  • Table 11. HIV Diagnosis: by End User(USD Million)
  • Table 12. HIV Diagnosis Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 13. HIV Diagnosis Hospitals , by Region USD Million (2018-2023)
  • Table 14. HIV Diagnosis Blood Banks , by Region USD Million (2018-2023)
  • Table 15. HIV Diagnosis Home Care Settings , by Region USD Million (2018-2023)
  • Table 16. HIV Diagnosis Others , by Region USD Million (2018-2023)
  • Table 17. South America HIV Diagnosis, by Country USD Million (2018-2023)
  • Table 18. South America HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 19. South America HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 20. South America HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 21. Brazil HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 22. Brazil HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 23. Brazil HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 24. Argentina HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 25. Argentina HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 26. Argentina HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 27. Rest of South America HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 28. Rest of South America HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 29. Rest of South America HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 30. Asia Pacific HIV Diagnosis, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 33. Asia Pacific HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 34. China HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 35. China HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 36. China HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 37. Japan HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 38. Japan HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 39. Japan HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 40. India HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 41. India HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 42. India HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 43. South Korea HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 44. South Korea HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 45. South Korea HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 46. Taiwan HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 47. Taiwan HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 48. Taiwan HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 49. Australia HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 50. Australia HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 51. Australia HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 55. Europe HIV Diagnosis, by Country USD Million (2018-2023)
  • Table 56. Europe HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 57. Europe HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 58. Europe HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 59. Germany HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 60. Germany HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 61. Germany HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 62. France HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 63. France HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 64. France HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 65. Italy HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 66. Italy HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 67. Italy HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 68. United Kingdom HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 69. United Kingdom HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 70. United Kingdom HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 71. Netherlands HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 72. Netherlands HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 73. Netherlands HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 74. Rest of Europe HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 75. Rest of Europe HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 76. Rest of Europe HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 77. MEA HIV Diagnosis, by Country USD Million (2018-2023)
  • Table 78. MEA HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 79. MEA HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 80. MEA HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 81. Middle East HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 82. Middle East HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 83. Middle East HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 84. Africa HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 85. Africa HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 86. Africa HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 87. North America HIV Diagnosis, by Country USD Million (2018-2023)
  • Table 88. North America HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 89. North America HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 90. North America HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 91. United States HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 92. United States HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 93. United States HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 94. Canada HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 95. Canada HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 96. Canada HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 97. Mexico HIV Diagnosis, by Type USD Million (2018-2023)
  • Table 98. Mexico HIV Diagnosis, by Test Type USD Million (2018-2023)
  • Table 99. Mexico HIV Diagnosis, by End User USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. HIV Diagnosis: by Type(USD Million)
  • Table 111. HIV Diagnosis Consumables (Assays and Kits & Reagents, and other Consumables) , by Region USD Million (2025-2030)
  • Table 112. HIV Diagnosis Instruments , by Region USD Million (2025-2030)
  • Table 113. HIV Diagnosis Software & Services , by Region USD Million (2025-2030)
  • Table 114. HIV Diagnosis: by Test Type(USD Million)
  • Table 115. HIV Diagnosis Antibody Tests (HIV-1 Screening Tests, HIV-1 Confirmatory Tests, and HIV-2 & Group O Diagnostic Tests) , by Region USD Million (2025-2030)
  • Table 116. HIV Diagnosis Viral Load Tests , by Region USD Million (2025-2030)
  • Table 117. HIV Diagnosis CD4 Tests , by Region USD Million (2025-2030)
  • Table 118. HIV Diagnosis Tests for Early Infant Diagnosis , by Region USD Million (2025-2030)
  • Table 119. HIV Diagnosis Tests for Viral Identification , by Region USD Million (2025-2030)
  • Table 120. HIV Diagnosis: by End User(USD Million)
  • Table 121. HIV Diagnosis Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 122. HIV Diagnosis Hospitals , by Region USD Million (2025-2030)
  • Table 123. HIV Diagnosis Blood Banks , by Region USD Million (2025-2030)
  • Table 124. HIV Diagnosis Home Care Settings , by Region USD Million (2025-2030)
  • Table 125. HIV Diagnosis Others , by Region USD Million (2025-2030)
  • Table 126. South America HIV Diagnosis, by Country USD Million (2025-2030)
  • Table 127. South America HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 128. South America HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 129. South America HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 130. Brazil HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 131. Brazil HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 132. Brazil HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 133. Argentina HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 134. Argentina HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 135. Argentina HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 136. Rest of South America HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 137. Rest of South America HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 138. Rest of South America HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 139. Asia Pacific HIV Diagnosis, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 141. Asia Pacific HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 142. Asia Pacific HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 143. China HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 144. China HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 145. China HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 146. Japan HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 147. Japan HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 148. Japan HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 149. India HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 150. India HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 151. India HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 152. South Korea HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 153. South Korea HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 154. South Korea HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 155. Taiwan HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 156. Taiwan HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 157. Taiwan HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 158. Australia HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 159. Australia HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 160. Australia HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 164. Europe HIV Diagnosis, by Country USD Million (2025-2030)
  • Table 165. Europe HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 166. Europe HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 167. Europe HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 168. Germany HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 169. Germany HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 170. Germany HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 171. France HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 172. France HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 173. France HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 174. Italy HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 175. Italy HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 176. Italy HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 177. United Kingdom HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 178. United Kingdom HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 179. United Kingdom HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 180. Netherlands HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 181. Netherlands HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 182. Netherlands HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 183. Rest of Europe HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 184. Rest of Europe HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 185. Rest of Europe HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 186. MEA HIV Diagnosis, by Country USD Million (2025-2030)
  • Table 187. MEA HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 188. MEA HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 189. MEA HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 190. Middle East HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 191. Middle East HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 192. Middle East HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 193. Africa HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 194. Africa HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 195. Africa HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 196. North America HIV Diagnosis, by Country USD Million (2025-2030)
  • Table 197. North America HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 198. North America HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 199. North America HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 200. United States HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 201. United States HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 202. United States HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 203. Canada HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 204. Canada HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 205. Canada HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 206. Mexico HIV Diagnosis, by Type USD Million (2025-2030)
  • Table 207. Mexico HIV Diagnosis, by Test Type USD Million (2025-2030)
  • Table 208. Mexico HIV Diagnosis, by End User USD Million (2025-2030)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global HIV Diagnosis: by Type USD Million (2018-2023)
  • Figure 5. Global HIV Diagnosis: by Test Type USD Million (2018-2023)
  • Figure 6. Global HIV Diagnosis: by End User USD Million (2018-2023)
  • Figure 7. South America HIV Diagnosis Share (%), by Country
  • Figure 8. Asia Pacific HIV Diagnosis Share (%), by Country
  • Figure 9. Europe HIV Diagnosis Share (%), by Country
  • Figure 10. MEA HIV Diagnosis Share (%), by Country
  • Figure 11. North America HIV Diagnosis Share (%), by Country
  • Figure 12. Global HIV Diagnosis share by Players 2023 (%)
  • Figure 13. Global HIV Diagnosis share by Players (Top 3) 2023(%)
  • Figure 14. Global HIV Diagnosis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 18. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 20. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 22. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 24. Thermo-Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo-Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 28. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Becton, Dickinson, and Company (United States) Revenue: by Geography 2023
  • Figure 30. Hologic, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Hologic, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Alere Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 36. Global HIV Diagnosis: by Type USD Million (2025-2030)
  • Figure 37. Global HIV Diagnosis: by Test Type USD Million (2025-2030)
  • Figure 38. Global HIV Diagnosis: by End User USD Million (2025-2030)
  • Figure 39. South America HIV Diagnosis Share (%), by Country
  • Figure 40. Asia Pacific HIV Diagnosis Share (%), by Country
  • Figure 41. Europe HIV Diagnosis Share (%), by Country
  • Figure 42. MEA HIV Diagnosis Share (%), by Country
  • Figure 43. North America HIV Diagnosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Siemens AG (Germany)
  • Roche Diagnostics (Switzerland)
  • Abbott Laboratories (United States)
  • Danaher Corporation (United States)
  • Thermo-Fisher Scientific Inc. (United States)
  • Merck KGaA (Germany)
  • Becton, Dickinson, and Company (United States)
  • Hologic, Inc. (United States)
  • Alere Inc. (United States)
  • Bio-Rad Laboratories (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 246 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global HIV Diagnosis Quantitative research analysis
Global HIV Diagnosis Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Siemens AG (Germany), Roche Diagnostics (Switzerland), Abbott Laboratories (United States), Danaher Corporation (United States), Thermo-Fisher Scientific Inc. (United States), Merck KGaA (Germany), Becton, Dickinson, and Company (United States), Hologic, Inc. (United States), Alere Inc. (United States) and Bio-Rad Laboratories (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Use of Home Access Kits and Instruments" is seen as one of major influencing trends for HIV Diagnosis Market during projected period 2023-2030.
The HIV Diagnosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global HIV Diagnosis Report?

Have a Query? Click Here

Other Related Reports

Vitiligo Drug Comprehensive Study by Type (ARN-4079, ATI-50001, AX-1602, Ruxolitinib Phosphate, VLRX-001, Others), Application (Clinic, Hospital, Others), Route of Administration (Oral, Topical), Dis...
$ 3750
Nicotine Addiction Treatment Comprehensive Study by Type (OMS-527, AT-1001, CTDP-002, EORA-101, URB-694, Others), Application (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies, Me...
$ 3750
Preventable Vaccines Comprehensive Study by Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Others), Application (Pneumococcal, Poliovirus, Hepatitis, Influen...
$ 3650
Influenza Medication Comprehensive Study by Type (Zanamivir, Oseltamivir phosphate, Peramivir, Other Influenza Medication), Application (Hospitals, Clinics, Pharmacies, Others), Treatment Type (Medic...
$ 3450
Raynauds Disease Treatment Comprehensive Study by Type (Primary, Secondary), Application (Hospital, Clinic, Others), Treatment (Medication, - Calcium Channel Blockers, - Vasodilator, Surgeries and Me...
$ 3750
Plasma Therapy Comprehensive Study by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics (Arthritis, Chronic Tendinitis, Bon...
$ 3750